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GABAB receptorN-type (Cav2.2) voltage-gated calcium channels (VGCC) transduce electrical activity into other cellular functions,
regulate calcium homeostasis and play a major role in processing pain information. Although the distribution
and function of these channels vary widely among different classes of neurons, they are predominantly
expressed in nerve terminals, where they control neurotransmitter release. To date, genetic and pharmacological
studies have identiﬁed that high-threshold, N-type VGCCs are important for pain sensation in disease models.
This suggests that N-type VGCC inhibitors or modulators could be developed into useful drugs to treat neuro-
pathic pain. This review discusses the role of N-type (Cav2.2) VGCCs in nociception and pain transmission
through primary sensory dorsal root ganglion (DRG) neurons (nociceptors). It also outlines the potent and selec-
tive inhibition of N-type VGCCs by conotoxins, small disulﬁde-rich peptides isolated from the venom of marine
cone snails. Of these conotoxins, ω-conotoxins are selective N-type VGCC antagonists that preferentially block
nociception in inﬂammatory painmodels, and allodynia and/or hyperalgesia in neuropathic painmodels. Another
conotoxin family, α-conotoxins, were initially proposed as competitive antagonists of muscle and neuronal
nicotinic acetylcholine receptors (nAChR). Surprisingly, however,α-conotoxins Vc1.1 and RgIA, also potently in-
hibit N-type VGCC currents in the sensory DRGneurons of rodents andα9 nAChR knockoutmice, via intracellular
signaling mediated by G protein-coupled GABAB receptors. Understanding how conotoxins inhibit VGCCs is
critical for developing these peptides into analgesics andmay result in better pain management. This article
is part of a Special Issue entitled: Calcium channels.
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Primary sensory DRG neurons (nociceptors) express membrane
receptors and ion channels that detect and transduce peripheral stimuli
into various cellular functions and closely regulate neuronal excitability.
Chronic inﬂammatory and neuropathic pain leads to nociceptor sensiti-
zation, allodynia (a painful response to a normally innocuous stimulus)
and hyperalgesia (an increased response to a painful stimulus) without
overt tissue damage. Pain sensation is transmitted through nociceptors
represented by small-diameter unmyelinated C and myelinated Aδ
neurons, whose cell bodies are located in the dorsal root ganglia
(DRG). Sensory DRG neurons project into the superﬁcial laminae of
the dorsal horn of the spinal cord and synapse with secondary sensory
neurons, which relay nociceptive signals to the thalamus [1].
Chronic pain is a major clinical, social and economic problem, with a
prevalence ranging from 8% to more than 60% of the population world-
wide [2–4]. Treatment options are still limited, with only 40–60% of
people achieving partial pain relief [5]. This maladaptive, relapsing
and remitting condition may result from a failure of nociceptors to
reset after the damaged tissues heal [6].
Multiple and complex pathophysiologicalmechanisms are responsi-
ble for the development and maintenance of chronic pain [3,7]. Altered
N-type VGCC function in sensory neurons has been implicated as one of
these mechanisms [8–11]. N-type VGCCs consist of a pore-forming α1B
subunit or Cav2.2 [12], which is encoded by the CACNA1B gene in
humans [13,14], and auxiliary β and α2δ subunits [15]. The phylogeny,
topology, subunit composition and role of N-type VGCCs in nociception
have been extensively studied [12,16,17] (see also Fig. 1 in Zamponi and
Currie in this Special Issue [18]). These channels are associated with
neurotransmitter release machinery in the nociceptor nerve terminals
and can be modulated by auxiliary Ca2+ channel subunits, synaptic
proteins, GPCR pathways, Ca2+ binding proteins and phosphorylation
[18–23]. It has been recognized that modulators of N-type VGCCs can
be used as drugs that target neuropathic pain. This review discusses
the role of N-type VGCCs in sensory neurons, and the rationale and lim-
itations behind usingω- and a subclass of α-conotoxins to target them.
2. Electrophysiological properties of N-type VGCCs in nociceptors
N-typeVGCCs signiﬁcantly contribute to synaptic transmission of pain
signals in DRG neurons, play major roles in pain information processing
by controlling neurotransmitter release from nociceptive nerve ﬁbers
[24–28], and modulate synaptic plasticity at the ﬁrst synapse of nocicep-
tive pathways [29]. N-type VGCCs are expressed in the cell soma of DRG
neurons [30] and nerve terminals, and co-localize with substance P
[31], a neuropeptide associated with pain and nociception [32]. N-type
VGCC localization was also observed in sensory nerve terminals in
superﬁcial laminae of the spinal dorsal horn using autoradiography
[33,34] and immunohistochemistry [31,35,36]. In spinal lamina I
neurons, N-type VGCCs have been shown to be major contributors
to monosynaptically-evoked postsynaptic currents [24].
N-type VGCC currents have been characterized in several different
neuronal cell types and there is general agreement that these channels
exhibit a single channel conductance of approximately 20 pS [37–39].
Gating kinetics, especially inactivation, are important biophysical proper-
ties to distinguish between multiple VGCCs types [40]. The main mecha-
nisms of N-type calcium channel inactivation are voltage-dependent
inactivation [41–43] and Ca2+-dependent inactivation [44–46].
Voltage-dependence of inactivation was demonstrated in various
neuronal preparations, including chick DRG sensory neurons [47].
Due to the multiple VGCC types expressed in most neurons, it is
often difﬁcult to distinguish between inactivation kinetics of multiple
currents in a cell or a complex inactivation process for a single VGCC
type [40]. This may contribute to the large variation in inactivation
kinetics of native N-type VGCCs in DRG neurons. Fast and slow inactiva-
tion of ω-conotoxin GVIA-sensitive (N-type) VGCC currents (>50% in1 s) was described in chick DRG neurons [48]. A two-component inacti-
vation of ω-conotoxin GVIA-sensitive VGCC currents was also observed
in rat DRG neurons [49]. The combined inactivation kinetics of macro-
scopic VGCC currents suggest co-expression of at least two kinetically
distinct N-type VGCC subunit combinations/variants in the same DRG
neuron. In addition, inactivation kinetics of the whole-cell calcium chan-
nel currentswere decelerated and often exhibited a non-inactivating cur-
rent component when DRG neurons were held at more depolarized HPs
[48–50]. The non-inactivating current was not due to residual L-type
channels, because the N-type channel currents could be isolated from
whole-cell currents [49]. Studies of recombinant N-type calcium chan-
nels contributed to identifying the inactivation properties of neuronal
(N-, P/Q- and R-type) channels [51] and deﬁne the speciﬁc roles of indi-
vidual Ca2+ channel subunits in this process [51–53]. VGCC inactivation
is an intrinsic process of the α1 subunit [54], however, other mecha-
nisms, including those mediated by auxiliary β subunits play a major
modulatory role [43]. Interestingly, voltage-dependent current inhibi-
tion occurs even in the closed-state, with “ultra-slow” kinetics, a pro-
cess largely regulated by the auxiliary β3 subunit [52].
To effectively control Ca2+ signaling, VGCCs inactivate in a process
called Ca2+-dependent inactivation (CDI). This results in a U-shaped
inactivation curve that can be revealed using a double-pulse protocol
[44,45,55]. Calmodulin has been identiﬁed as an important Ca2+ sensor
thatmediates thismechanismby interactingwith the Ca2+ inactivation
region of the VGCC. The Ca2+ inactivation region, localized in the
C-terminal domain of the α1B subunit (see Fig. 1 in Zamponi and Currie
in this Special Issue [18]), is highly sensitive to Ca2+ buffering [56].
Another hallmark of CDI is that Ba2+ is typically less effective than
Ca2+ at inactivating the channels [46]. CDI can also be removed
by increasing the Ca2+ buffering capacity of the cytoplasm by in-
troducing exogenous buffers [44,57]. Our current understanding
of Ca2+-dependent modulation of native and recombinant VGCCs
has been reviewed [23,46]. However, it is important to note that
the U-shaped inactivation curve might also result from a purely
voltage-dependent process in N-type VGCCs [58].
As discussed in Section3.1, the characteristics of block and/or recovery
from block by some ω-conotoxins were robustly dependent on the HP
and degree of voltage-dependent inactivation of N-type VGCCs.
3. N-type VGCCs: therapeutic targets in neuropathic pain
The roles of N-type VGCCs in pain pathways have been elucidated
genetically and pharmacologically [10,11,25,59]. N-type VGCC inhibition
can cause analgesia, as demonstrated with the use of selective channel
antagonists in animal pain models or gene knockout mice [10,11,25,59].
These ﬁndings have been reviewed by several groups [60–63].
In the DRG neurons of mice lacking Cav2.2, N-type VGCC currents
were almost completely abolished and nociceptive responses reduced
[64]. Essentially, there was no signiﬁcant difference between acute
nociception in wild-type (Cav2.2+/+) and mutant (Cav2.2−/−) mice,
but Cav2.2 deﬁciency consistently delayed inﬂammatory pain develop-
ing in the formalin test. Most remarkably, Cav2.2−/− mice exhibited
notably fewer neuropathic pain symptoms, including mechanical
allodynia and thermal hyperalgesia induced by spinal nerve ligation
[65].
Given that allodynia and hyperalgesia are clinical neuropathic
pain symptoms in humans, studies with unique animal research
models should facilitate development of clinical drugs that modulate
N-type VGCC activity.
3.1. Cav2.2 channel sensitivity to ω-conotoxins
ω-Conotoxins are disulﬁde-rich peptides composed of 24–31
amino acids, isolated from venomous marine predatory cone snails
(Table 1). They have a high basic amino acid residue content and
common cysteine scaffold that stabilizes the four-loop framework.
Table 1
Sequences of native ω-conotoxins inhibiting mammalian Cav2.2 (N-type) channels.
Conus species and conotoxin Sequence and disulﬁde connectivity Target VGCC Net charge Reference
C. consors
CnVIIA Cav2.2 +5 [66]
C. catus
CVIA CKSTGASCRRTSYDCCTGSCR–SGRC* Cav2.2 +5 [67]
CVIB CKGKGASCRKTMYDCCRGSCR–SGRC* Cav2.1 and Cav2.2 +7 [67]
CVIC CKGKGQSCSKLMYDCCTGSCSR-RGKC* Cav2.1 and Cav2.2 +6 [67]
CVID CKSKGAKCSKLMYDCCSGSCSGTVGRC* Cav2.2 +5 [67]
CVIE CKGKGASCRRTSYDCCTGSCRS–GRC* Cav2.2 +6 [68]
CVIF CKGKGASCRRTSYDCCTGSCRL–GRC* Cav2.2 +6 [68]
C. fulmen
FVIA CKGTGKSCSRIAYNCCTGSC–RSGKC* Cav2.2 +6 [69]
C. geographus
GVIA CKSOGSSCSOTSYNCCR-SCNOYTKRCY* Cav2.2 +5 [70]
C. magus
MVIIA CKGKGAKCSRLMYDCCTGSC-R-SGKC* Cav2.2 +6 [71]
MVIIC CKGKGAPCRKTMYDCCSGSCGR-RGKC* Cav2.1 and Cav2.2 +7 [72]
MVIID CQGRGASCRKTMYNCCSGSCNR-RGRC* Cav2.1 and Cav2.2 +7 [73,74]
C. radiatus
RVIA CKPOGSOCRVSSYNCCS-SCKSYNKKCR* Cav2.2 +7 [75,76]
C. striatus
SVIB CKLKGQSCRKTSYDCCSGSCGR-SGKC* Cav2.1 and Cav2.2 +6 [77]
SO3 CKAAGKPCSRIAYNCCTGSCRS–GKC* Cav2.1 and Cav2.2 +6 [78]
C. tulipa
TVIA CLSOGSSCSOTSYNCCR-SCNOYSRKCR* Cav2.2 +5 [79]
O, Hydroxyproline; *, C-terminal amidated.
1621D.J. Adams, G. Berecki / Biochimica et Biophysica Acta 1828 (2013) 1619–1628Typically, ω-conotoxins selectively inhibit N-type VGCCs in
nociceptors, so are considered attractive molecules for drug design. The
development, diversity, synthesis, pharmacology, structure–activity
relationships and analysis of ω-conotoxin–VGCC interactions have
comprehensively been reviewed [61,80–84]. Positive charges,
especially Lys2, and residues in loop 2, especially the hydroxyl
group on residue Tyr13, are important for afﬁnity to the N-type calcium
channels [85–87]. The lack of sequence homology amongω-conotoxins,
as in snake and spider toxins, suggests that the overall three-
dimensional structure and/or charge distribution underpin their inter-
action with N-type VGCCs [88]. Accordingly, ω-conotoxins GVIA and
MVIIA inhibit the same calcium channel subtype (Cav2.2) despite their
remarkably low sequence homology. The two ω-conotoxins with the
most sequence homology, MVIIA andMVIIC, target Cav2.2 VGCCs. How-
ever, MVIIC is also a potent antagonist of Cav2.1 VGCCs [72] (Table 1).
Typically, the α2δ auxiliary subunit reduces ω-conotoxin afﬁnity
for Cav2.2 VGCCs [68,89]. Recovery of Cav2.2 currents from block is
more efﬁcient at non-physiological hyperpolarized HP values than
at depolarized (physiological) HP. This suggests that ω-conotoxins
have higher afﬁnity for channels in the inactivated state [90]. Efﬁcient
recovery from block has been demonstrated in Xenopus oocytes
co-expressingα1B,α2δ1 and the non-inactivatingβ2a subunit [68]. Posi-
tion 10 (Hyp, Arg and Lys in GVIA, MVIIA and CVID, respectively) in the
amino acid sequence of ω-conotoxins also inﬂuences reversibility [89].
The kinetics and recovery of Cav2.2 channels from ω-conotoxin
block are also correlated with extracellular divalent cation concentra-
tion. Block is rapidly reversible in divalent cation-free external solution
but exhibits slow recovery in the presence of 3 mM Ba2+ [91]. In-
creased external Ba2+ also reduces the potency and the rate of MVIIC
block [92,93]. This effect of Ba2+ can be explained by the existence of
a Ca2+-binding motif [94] close to the toxin-binding domain on theextracellular loop in domain III of the Cav2.2 channel [95,96]. However,
the site(s) where N-type VGCCs interact with ω-conotoxins, and their
mode of action, are yet to be fully elucidated. Nevertheless, the extra-
cellular linker between S5 and P-region in domain III, which forms
part of the Cav2.2 channel pore, is a critical motif for binding [96]
and suggests a pore blocking model for ω-conotoxins. Subsequently,
the residue Gly1326 in the linker was shown to be amajor determinant
ofω-conotoxin binding, because mutation of glycine to proline fully re-
versed channel block byGVIA andMVIIA [95]. Therefore, single residues
on the toxin molecule or VGCC can signiﬁcantly affectω-conotoxin dis-
sociation. Lewis and colleagues have recently presented a hypothetical
docking model of ω-conotoxin MVIIA to a calcium channel homology
model [84] built from a bacterial sodium channel crystal structure [97].
In this model, MVIIA interacts with all four Cav2.2 subunits and physi-
cally occludes the channel pore.
N-type calcium channel diversity can be attributed to their auxiliary
subunit composition andN-type VGCCα1B subunit tissue-speciﬁc splice
variants. A series of Cav2.2 channel alternative splice variants have been
reported inmammalian neurons [98] (see also the reviewby Lipscombe
et al in this Special Issue [99]). Of these, a large sequence deletion, in-
cluding a synprint site in the II–III loop region (Cav2.2-Δ1), impaired
the binding of SNARE protein syntaxin to the channel and dramatically
reduced channel sensitivity toω-conotoxin MVIIA or GVIA [100]. These
ﬁndings suggest that the intracellular II–III linker region is an important
determinant of N-type channel function and pharmacology. Other
Cav2.2 channel splice variants with skipping/inclusion of exon(s),
encoding a 21-amino acid cassette and the 382/263 amino acid se-
quence in the II–III loop region, have been reported for rat, mouse and
human Cav2.2, respectively [100–102]. Resulting variants may critically
affect neurotransmitter release. The 21 amino acid insertion in the II–III
cytoplasmic loop region has been shown to contribute to controlling the
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[103].3.1.1. ω-Conotoxins as molecular tools
GVIA, MVIIA and CVID have been extensively used as research
tools to help deﬁne the distribution and physiological roles of speciﬁc
calcium channels (Table 1) [67,104,105]. VGCCs show considerable
heterogeneitywithω-conotoxin sensitivity. Inmammalian DRGneurons,
the contribution of N-type VGCC currents to whole-cell VGCC currents
was evaluated using speciﬁc and selective ω-conotoxins [36,49,64,65,
86,106–111]. GVIA- and MVIIA-resistant, but CVID-sensitive, transmitter
release from preganglionic nerve terminals has been demonstrated in rat
parasympathetic ganglia [112]. GVIA-resistant N-type channel currents
have also been reported in frog sympathetic neurons [39], and in PC12
cells, GVIA unveiled two types of N-type channel currents: reversible
and irreversible [37].3.1.2. ω-Conotoxins in drug development
ω-Conotoxin MVIIA (Ziconotide, Prialt) has been approved by the
Food and Drug Administration (FDA) as an intrathecal analgesic for
therapeutic use (Fig. 1). Despite a narrow therapeutic window, be-
cause of its substantial central nervous system side effects [113],
Ziconotide is indicated for the management of severe chronic pain
in people who are intolerant or refractory to other treatment, such
as systemic analgesics, adjunctive therapies or intrathecal morphine.
Case studies have reported that using Ziconotide in combination
with morphine, baclofen or hydromorphone reduced side effects
[114]. For example, low doses of Ziconotide and morphine allowed
safe and rapid control of oral opioid-refractory malignant pain [115].
ω-Conotoxin CVID (AM336, Leconotide, CNSB004) [67] has an im-
proved side effect proﬁle compared with MVIIA [116]. CVID reduced
hyperalgesia in a rat model of neuropathic pain after it was adminis-
tered intravenously [117]. Relevare Pharmaceuticals™ Ltd (Australia)
reported that CNSB004's analgesic activitywas signiﬁcantly potentiated
when co-administered with opioid or certain non-opioid analgesics. It
was also conﬁrmed that CVID inhibits neurally evoked release of sub-
stance P in the rat spinal cord [116]. Although GVIA, MVIIA and CVID
preferentially block allodynia or hyperalgesia in neuropathic pain
models and nociception in inﬂammatory pain models, their efﬁcacy in
acute pain models in rodents remains controversial [116,118–125].
The kinetics of ω-conotoxin–VGCC interactions, particularly the
residence time of the interaction, can be a key factor in determining
the effectiveness ofω-conotoxins and affect control of their administra-
tion [126]. The reversibility of block may be correlated with how effec-
tively ω-conotoxins reverse different painful conditions in vivo [127].Fig. 1. Three-dimensional representation of ω-conotoxin MVIIA (Protein Data Bank
accession code 1TTK) and α-conotoxin Vc1.1 (Protein Data Bank accession code
2H8S). The backbone is gray and disulﬁde bonds are yellow (blue, nitrogen; red,
oxygen; cyan, carbon). Figure created with Visual Molecular Dynamics (VMD
1.9.1) software using data from the Protein Data Bank.CVIE and CVIF are recently characterized, potent N-type VGCC-
selective ω-conotoxins from Conus catus [68]. In spinal cord slices,
these peptides reversibly inhibited excitatory synaptic transmission be-
tween primary afferents and dorsal horn superﬁcial lamina neurons. In
the rat partial sciatic nerve ligationmodel of neuropathic pain, CVIE and
CVIF also signiﬁcantly reduced allodynic behavior [68]. However,
further studies are needed to clarify the therapeutic potential of
these compounds.
ω-Conotoxin FVIA, isolated from Conus fulmen, shows better revers-
ibility than MVIIA [69]. FVIA effectively and dose-dependently reduced
nociceptive behavior in a formalin test and neuropathic pain models,
and reduced mechanical and thermal allodynia in the tail nerve injury
rat model [69].
3.2. Conopeptide mimetics and small molecule N-type VGCC antagonists
Considerable effort has beenmade to develop systemically available,
peptidic or non-peptidic, small-molecule, N-type VGCC inhibitors.
These inhibitors could represent the next generation of drugs to treat
chronic pain and many of them are being assessed in clinical trials
[61,128].
Conopeptide mimetics are usually small molecules that resemble
(or mimic) a domain of an active conopeptide and retain pharmacolog-
ical activity. ω-Conopeptide mimetic design is based on reconstruction
of binding epitope(s) revealed by nuclear magnetic resonance, alanine-
scanning data [129] and/or molecular modeling [130]. Cyclic pentapep-
tides, containing residues of loop 2 of CVID, were found to be inactive at
the P/Q-type VGCC but active at the N-type VGCC [130]. However, the
IC50 values of these compounds (~20 μM) are three to four orders of
magnitude lower than those of MVIIA and CVID.
Additional methods created compounds that could block N-type
VGCCs and/or neurotransmitter release. Non-peptidic small molecules
were developed on scaffold-based design [131], and other active
compounds were developed from modifying state-dependent
Cav2.2 channel inhibitors [132–134]. Recently, Tranberg et al. devel-
oped a subset of anthranilamide-derived ω-conotoxin GVIA mimetics,
which showedmodest Cav2.2 inhibitory effects in three separate assays,
including a HEK cell system for heterologous expression of Cav2.2
VGCCs (IC50 values of ~150 μM) [135]. However, there has been little
success in decreasing the size of ω-conotoxins without signiﬁcant loss
of biological activity, indicating thatω-conotoxin mimetics is very chal-
lenging [129].
Another approach, based on structure–activity relationships (SAR),
resulted in a series of pyrazole-derived N-type channel blockers.
These compounds potently inhibited heterologously expressed Cav2.2
channel currents (with estimated IC50 values of ~100–500 nM) and
showed efﬁcacy in rat models of inﬂammatory and neuropathic pain
[136].
Gabapentin (Fanatrex, Gabarone, Neogab, Gralise, Neurontin and
Nupentin) and pregabalin (Lyrica) are two of the three FDA-approved
analgesic drugs that act on N-type VGCCs. They are used to treat epilepsy
and neuropathic pain [137–140]. Both compounds are γ-aminobutyric
acid (GABA) analogs with no GABAergic action, but have afﬁnity towards
the auxiliaryα2δVGCC subunit [141] that is up-regulated inDRGneurons
in various pain states [142–144]. Pregabalin reduces synaptic vesicle re-
lease from cultured hippocampal neurons [145]. For further details on
gabapentin, see the research article by Gee et al. [146] and reviews
[138,139,146,147]. Although they effectively treat neuropathic pain,
gabapentin and pregabalin have various adverse effects andmay provoke
withdrawal syndrome.
Stephens and colleagues designed small peptides that correspond
with the Cav2.2 channel N-terminus (amino acids 45–55) or amino
acids 377–393 on the Cav2.2 channel I–II loop α interaction domain
[148]. These synthetic Cav2.2 channel peptides have been shown to re-
duce whole-cell Ca2+ current amplitude, attenuate noradrenaline-
induced G protein modulation, and suppress synaptic transmission.
Table 2
Sequences of α-conotoxins inhibiting mammalian Cav2.2 (N-type) channels.
Conus species and
conotoxin
Sequence and disulﬁde connectivity Net charge Reference
C. aulicus
AuIB 0 [174]
C. pergrandis
PeIA GCCSHPACSVNHPELC* 0 [175]
C. regius
RgIA GCCSDPRCRYR——CR +3 [176]
C. victoriae
Vc1.1 GCCSDPRCNYDHPEIC* −1 [176]
Cyclized Vc1.1 −2 [177]
Vc1.2 GCCSNPACMVNNPQIC* +1 [178]
*, C-terminal amidated; the sequence in italic represents the linker in cyclized Vc1.1.
Fig. 2. Docking (top view) of α-conotoxin Vc1.1 to the heterodimerization interface of
human GABABR. The homology model of GABABR1, 1b isoform VFT was created using
GABABR2 VFT crystal structure (Protein Data Bank accession code 4F11). The VFT
dimer was generated using the closed conformer of the metabotropic glutamate
receptor-subtype 1 (mGluR1) (Protein Data Bank accession code 1EWK), according
to the method described by Geng et al. [188]. (A) ‘Autodock’ simulation, with variable
toxin side chain torsion angles and ‘rigid’ receptor. (B) ‘HEX’ simulation, with shape
complementarity, assuming rigid toxin and rigid receptor. In both A and B, α-helices
and β-strands on GABABR1 (red) and GABABR2 (blue) are visualized (Dr Andrew
Hung, unpublished data).
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lular signaling pathways. Another novel approach, involving lentiviral
vector delivery of a tethered-toxin, resulted in the cell-speciﬁc and
cell-autonomous silencing of neurotransmission and long-lasting sup-
pression of chronic pain in mice [149].
4. Inhibition of N-type channels via GPCR
Numerous neurotransmitters shorten action potential duration in
DRGneurons [150]. The underlying cellularmechanism for this involves
inhibition of VGCCs [151]. GPCR-modulation of Cav2.2 VGCCs by intra-
cellular signal transduction pathways has recently been reviewed
[11,18,152–154]. Here, we will brieﬂy discuss Cav2.2 channel current
inhibition caused by GABAB receptor activation.
GABA is a major inhibitory neurotransmitter that can activate
ionotropic (GABAA) or metabotropic (GABAB) receptors [155,156]. In
neurons, functional GABAB receptors (GABABR) are assembled from
GABABR1 and GABABR2 subunits and members of a potassium channel
tetramerization domain-containing protein subfamily [157,158]. GABA-
BR1 is responsible for ligand binding and GABABR2 is responsible for G
protein coupling [159–164].
GABABR activation inhibits Ca2+ inﬂux throughVGCCs in amembrane-
delimited manner, interpreted as a direct and voltage-dependent
binding of G protein βγ subunit to the Cav2.2 channel [165–167].
The various G protein α subunits trigger voltage-independent intra-
cellular signaling pathways, which may converge on VGCCs to either
up-regulate or inhibit their activities [18,153,154]. Impaired GABABR
function is implicated in various neurological diseases, including
spasticity, epilepsy, pain and drug abuse [158].
4.1. Analgesic effects of GABAB receptor activation
GABABR activation by agonists is a well-established mechanism for
relieving pain [168]. GABA and baclofen (a GABA derivative and speciﬁc
GABABR agonist) bind to the ligand binding site in a large extracellular
Venus ﬂytrap module (VFT) of the GABABR1 subunit [158]. Baclofen
(Lioresal) is indicated for the management of severe spasticity, but it
has also been used to manage numerous neuropathic pain states [169]
and recommended as an adjuvant analgesic for relieving cancer pain
[170]. In animals, baclofen reduces mechanical allodynia and
hyperalgesia in chronic neuropathic pain models [160]. Interestingly,
it has also shown efﬁcacy in visceral pain models, indicating that the
GABAergic pathway is a potential target for drugs to treat conditions re-
lated to chronic visceral pain, such as irritable bowel syndrome
[171,172]. Together, these ﬁndings demonstrate the involvement of
GABABRs in afferent pain pathways.
4.2. α-Conotoxin modulation of N-type VGCCs via GABAB receptors
α-Conotoxins are relatively short (12–16 amino acid) peptides,
exhibit a cysteine framework with two disulﬁde bonds in C1–C3 and
C2–C4 connectivity, and often have an amidated C-terminus (Table 2)
[173]. They are typically classiﬁed as antagonists of the muscle and
neuronal nicotinic acetylcholine receptors (nAChR) [76,179] and
have exquisite nAChR subtype selectivity [173]. For example,
α-conotoxins Vc1.1, RgIA, and PeIA are potent antagonists of α9α10
nAChRs [173] which are expressed in neuronal and non-neuronal cells
(see [180]). However, there is no evidence of functionalα9α10 nAChRs
expressed in rat DRG neurons (DJ Adams and L Motin, unpublished
data) [181].
It has been shown that the synthetic cyclization of theseα-conotoxins
with peptide linkers stabilizes them and improves their biopharmaceuti-
cal properties [177,182]. RgIA and Vc1.1 have also been shown to effec-
tively relieve mechanical allodynia in rat models of neuropathic pain
[180,183,184]. However, the proposed role of α9α10 nAChRs in
mediating the anti-allodynic effects of α-conotoxins has been
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N-type VGCC currents in rat sensory DRG neurons (Fig. 1) [176] and
α9 nAChR knockout (−/−) mice sensory DRG neurons [185]. Vc1.1
and RgIA do not interact directly with N-type VGCCs (Cav2.2), but via
a novel, G protein-coupled GABABR-mediated mechanism [80,176].
This GPCR-mediated modulation of N-type VGCCs is largely mediated
via voltage-independent intracellular pathway(s), requiring src tyro-
sine kinase activity, and does not appear to directly involve a G protein
βγ-subunit. An interesting aspect of Vc1.1-induced modulation of
N-type VGCCs is use-dependence, which was demonstrated by the
rate of inhibition onset varying with the frequency and duration of de-
polarization or opening of calcium channels [176].
It was recently shown that expression of both GABABR subunits is
needed for inhibition of Cav2.2 channels by α-conotoxins Vc1.1 and
RgIA. This was demonstrated using subunit-speciﬁc transient knock-
down of GABABRs with siRNA in rat DRG neurons [186]. In neurons
with GABABR knockdown, inhibition of N-type VGCC current by baclo-
fen, Vc1.1, and RgIA was signiﬁcantly less than that of the control. Sim-
ilarly, Cav2.2 channel inhibition by Vc1.1 and RgIA needed both human
GABABR subunits to be functionally expressed in the HEK-293 cell heter-
ologous expression system [186].
How this subclass of α-conotoxins interacts with GABABRs and
which receptor domains are critical for α-conotoxin binding/interac-
tion are unknown. GABABR1 VFT involvement in this is unlikely, since
Vc1.1 and RgIA could not displace binding of the selective GABABR an-
tagonist [3H]CGP54626 to transiently expressed human GABABRs in
HEK-293 cells [187] or rat DRG neurons (S Nevin and DJ Adams,
unpublished data).
Geng et al. elegantly demonstrated that the GABABR2 ectodomain
directly interacts with the GABABR1 ectodomain to stabilize the
agonist-bound GABABR1 conformation [188]. Crystal structure data
revealed speciﬁc heterodimer contacts, a polar heterodimeric inter-
face between the GABABR ectodomains and dynamic interdomainFig. 3. Schematic of a presynaptic terminal and postsynaptic neuron and the signal transmis
VGCCs in the plasma membrane of the presynaptic terminal. Transient elevation of intracellula
brane and the release of neurotransmitters (black dots) into the synaptic cleft. Extracellular neu
postsynaptic neurons and can potentially trigger action potentials in the postsynaptic cell. (B)
channels [96]. (C) Analgesic α-conotoxins inhibit Cav2.2 channels via G protein-coupled GABAB
cellular signaling involving a c-srk tyrosine kinase [176].hinge angles in GABABR2 [188]. Molecular dynamics simulations
of the interaction between α-conotoxin Vc1.1 and human GABABR
suggest key interaction sites at the interface between the GABABR
ectodomains (Fig. 2). However, further mutational analyses of the
putative residues involved are needed to clarify and reﬁne Vc1.1
binding site(s).
In primary cultures of CA3–CA1 hippocampal neurons, the proximal
C-terminus of the GABABR1 was identiﬁed as an essential molecular
domain that mediates the GABABR1a–G protein βγ subunit–Cav2.2
channel assembly [189]. This compartmentalization of the GABABR1,
Gβγ and Cav2.2 channel in a signaling complex is needed for presynaptic
inhibition at hippocampal synapses. Mutagenesis of the intracellular
C-terminus of GABABR at speciﬁc GABABR2/G protein α subunit interac-
tion sites could unveil the involvement of the Gα subunit in mediating
the effect of α-conotoxins.
It is becoming increasingly clear that in the cell membrane, the
Cav2.2 channel nano-environment includes a large protein network
dedicated to (GPCR-mediated) signaling, activity-dependent cyto-
skeleton remodeling and intracellular Ca2+ homeostasis. A quantitative
proteomic study suggests that GABABRs strongly interact with Cav2
channels in the mammalian brain [190].
Remarkably, two splice isoforms, Cav2.2e[37a] and Cav2.2e[37b],
at the C-terminus of Cav2.2 channels critically affect GPCRmodulation
in nociceptors. A tyrosine, encoded within exon e[37a] of the N-type
VGCC pore-formingα1B subunit and absent in Cav2.2e[37b], is essential
for voltage-independent inhibition of these channels [18,191]. Exon
[37a], preferentially expressed in nociceptive neurons, renders the
Cav2.2 channel susceptible to a novel form of G protein-mediated in-
hibition by baclofen and opiates [191]. It also supports transmission
of speciﬁc types of pain stimuli [192,193], making Cav2.2e[37a] a key
target for analgesic drugs. It remains to be determined whether the
Cav2.2e[37a] isoform is more susceptible to inhibition by α-conotoxins
Vc1.1 and RgIA than Cav2.2e[37b].sion at a typical chemical synapse. (A) Membrane depolarization opens N-type (Cav2.2)
r Ca2+ concentration results in the fusion of synaptic vesicles with the presynaptic mem-
rotransmitters bind to speciﬁc receptors (gray shaded shape) in the plasmamembrane of
ω-Conotoxins inhibit neurotransmission by occluding the ion-conducting pore of Cav2.2
receptors. This inhibition is largely voltage-independent and mediated by complex intra-
1625D.J. Adams, G. Berecki / Biochimica et Biophysica Acta 1828 (2013) 1619–16284.3. α-Conotoxins relieve pain by acting on multiple targets
The native peptide isolated from the cone snail venom of Conus
victoriae, vc1a, potently inhibits α9α10 nAChRs, but is inactive in
rat neuropathic pain assays [183,194]. Several structural analogs of
Vc1.1 retain activity at α9α10 nAChRs, but lose their anti-allodynic
effect [183], suggesting that a target other than the α9α10 nAChR
contributes to the anti-nociceptive activity of Vc1.1. Sciatic nerve injury
pain models of α9 nAChR-knockout mice develop mechanical allodynia
indistinguishable fromwild-type, which persist for >3 weeks [195]. Fur-
thermore, antagonismofα9α10nAChR is neither necessary nor sufﬁcient
to reverse allodynia produced byα-conotoxins Vc1.1, AuIB andMII [174].
It was demonstrated that GABABR-dependent inhibition of N-type
VGCCs can mediate the sustained anti-allodynic actions of α-conotoxins
Vc1.1 and AuIB. This is because the pretreatment with the selective
GABABR antagonist SCH 50911 antagonizes the anti-allodynic effect of
intramuscularly applied Vc1.1 [174]. Intrathecal administration of
α-conotoxins Vc1.1, and AuIB and MII also reduced mechanical
allodynia in neuropathic rats [196]. In rat spinal cord slices, excitatory
postsynaptic currents recorded from neurons in the superﬁcial dorsal
horn in response to dorsal root stimulation were inhibited by baclofen
but not Vc1.1 [196]. An explanation for the failure to observe the
modulation of primary afferent synaptic transmission by α-conotoxin
Vc1.1 may be the presence of an alternative Cav2.2 channel splice
variant(s) at the presynaptic nerve terminal [191–193,197] which
is resistant to α-conotoxin inhibition. An alternative explanation is
signaling mechanism differences between DRG cell bodies and
their central nerve terminals (see [198]). α-Conotoxin MII, a potent
α3β2 nAChR antagonist, does not inhibit N-type VGCCs in DRG neurons
but produces an anti-allodynic action when applied intrathecally. This
suggests that inhibiting α3-subunit-containing nAChRs in the spinal
cord can also alleviate allodynia [198].
5. Concluding remarks and future directions
N-type VGCC inhibition by conotoxins can cause analgesia. A number
of conopeptides have shown efﬁcacy in vivo and are in preclinical devel-
opment to create improved drugs to treat chronic and neuropathic pain.
ω-Conotoxins have not yet been shown to differentiate between various
Cav2.2 VGCC splice variants. Given that they are applied intrathecally to
minimize side effects, they have a limited therapeutic window. Clearly,
selective block of presynaptic Cav2.2 channels responsible for transduc-
tion of nociceptive information at synapses in the superﬁcial dorsal horn
(Fig. 3) is desirable.
Theoretically, a voltage-independent modulatory pathway in DRG
neurons expressing the Cav2.2[37a] channel splice variant could make
these neurons more susceptible to modulation by α-conotoxins. Further
studies, involving co-administration of ω-conotoxins and α-conotoxins,
might help to ﬁne tune the anti-allodynic effects of these peptides.
Understanding the molecular mechanisms of action of conotoxins
will lead to newways to regulate VGCC block andmodulation in normal
and diseased states of the nervous system.
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